Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1

Status

Recruiting 7Completed 2Active not recruiting 2

Sponsor Class

OTHER_GOV 1OTHER 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Prostatic Neoplasms 501Carcinoma, Renal Cell 165Urinary Bladder Neoplasms 135Carcinoma, Transitional Cell 71Carcinoma, Non-Small-Cell Lung 57Kidney Neoplasms 56Melanoma 53Breast Neoplasms 51Ovarian Neoplasms 43Neoplasms 41Neoplasm Metastasis 40Colorectal Neoplasms 38Lung Neoplasms 27Squamous Cell Carcinoma of Head and Neck 26Non-Muscle Invasive Bladder Neoplasms 26Uterine Cervical Neoplasms 25Stomach Neoplasms 25Sarcoma 24Endometrial Neoplasms 24Triple Negative Breast Neoplasms 21Pancreatic Neoplasms 19Esophageal Neoplasms 18Carcinoma, Hepatocellular 17Wilms Tumor 16Head and Neck Neoplasms 16Small Cell Lung Carcinoma 15Urologic Neoplasms 14Colonic Neoplasms 14Urethral Neoplasms 13Ureteral Neoplasms 13

Interventions

padeliporfin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × Localized Prostate Cancer × Genitourinary × Clear all
NCT03814252 2025-09-22

PRO-TULSA-PC

Turku University Hospital

Phase NA Active not recruiting
62 enrolled
Genitourinary

Localized Prostate Cancer

NCT03315754 2024-12-20

Study of the Efficacy, Safety and Quality of Life After TOOKAD® Soluble (VTP) for Intermediate Risk Prostate Cancer.

Steba Biotech S.A.

Phase 2 Active not recruiting
50 enrolled 8 charts
Genitourinary

Localized Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡